Disease · MONDO_0004456

cocaine abuse

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cocaine abuse. Diseases, record MONDO_0004456. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004456

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cocaine abuse; Open Targets
Open Targets ID: MONDO_0004456; Open Targets
Disease Ontology: DOID:809; Disease Ontology
Highest stage of its drugs: Phase 3, for 4 of its 28 drugs, from ClinicalTrials.gov; Open Targets

Drugs28

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BUPRENORPHINE	CHEMBL511142	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
CITICOLINE	CHEMBL1231700	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHADONE	CHEMBL651	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NEFAZODONE	CHEMBL623	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BACLOFEN	CHEMBL701	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DESIPRAMINE	CHEMBL72	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
RISPERIDONE	CHEMBL85	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ARIPIPRAZOLE	CHEMBL1112	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ATOMOXETINE	CHEMBL641	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DISULFIRAM	CHEMBL964	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 28

See all 28 drugs

Targets38

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DRD2	D(2) dopamine receptor	5	D2-like dopamine receptor agonist; Dopamine D2 receptor agonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist; Dopamine receptor agonist	Phase 2	https://conductscience.org/library/genes/1813	Drugs and targets
SLC6A2	Monoamine transporter	5	Monoamine transporter inhibitor; Norepinephrine transporter inhibitor	Phase 3	https://conductscience.org/library/genes/6530	Drugs and targets
SLC6A4	Monoamine transporter	4	Monoamine transporter inhibitor; Serotonin transporter inhibitor	Phase 3	https://conductscience.org/library/genes/6532	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	3	Serotonin 2a (5-HT2a) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3356	Drugs and targets
OPRM1	Mu-type opioid receptor	3	Mu opioid receptor agonist; Mu opioid receptor antagonist	Phase 3	https://conductscience.org/library/genes/4988	Drugs and targets
SLC6A3	Monoamine transporter	3	Dopamine transporter inhibitor; Monoamine transporter inhibitor	Phase 2	https://conductscience.org/library/genes/6531	Drugs and targets
ACHE	Acetylcholinesterase	2	Acetylcholinesterase inhibitor; Cholinesterases; ACHE & BCHE inhibitor	Phase 1	https://conductscience.org/library/genes/43	Drugs and targets
DRD3	D2-like dopamine receptor	2	D2-like dopamine receptor agonist; Dopamine receptor agonist	Phase 2	https://conductscience.org/library/genes/1814	Drugs and targets
DRD4	D2-like dopamine receptor	2	D2-like dopamine receptor agonist; Dopamine receptor agonist	Phase 2	https://conductscience.org/library/genes/1815	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	2	Serotonin 2c (5-HT2c) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3358	Drugs and targets

1 to 10 of 38

See all 38 targets

Trials29

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00929253	Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)	Not applicable	170	2022-05-27	Opiate Addiction	BUPRENORPHINE	Its record names the disease	ClinicalTrials.gov
NCT00223236	Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence	Phase 3	44	2014-08-11	Mania, Hypomania, Cocaine Abuse, Cocaine Dependence	CITICOLINE	Its record names the disease	ClinicalTrials.gov
NCT00373880	Effects of Aripiprazole on Cocaine Craving and Self-Administration	Phase 2	26	2017-09-11	Cocaine Abuse	ARIPIPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00218543	Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)	Phase 2	20	2012-07-04	Attention Deficit Disorder With Hyperactivity, Cocaine-Related Disorders	ATOMOXETINE	Its record names the disease	ClinicalTrials.gov
NCT02141620	n-Acetylcysteine and Cocaine	Early phase 1	15	2016-10-06	Cocaine Abuse, Cocaine Dependence	ACETYLCYSTEINE	Its record names the disease	ClinicalTrials.gov
NCT02563769	Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study	Phase 1	10	2023-11-03	Cocaine Dependence, Cocaine Addiction, Cocaine Abuse, Cocaine-Related Disorders	CLAVULANIC ACID, COCAINE	Its record names the disease	ClinicalTrials.gov
NCT00913484	Disulfiram for Cocaine Abuse in Buprenorphine Treatment	Phase 2	177		Cocaine Dependence, Opioid Dependency	DISULFIRAM	Its record names the disease	ClinicalTrials.gov
NCT00218166	Effectiveness of GABA Agonists in Reducing the Reinforcing Effects of Cocaine	Phase 2	78		Cocaine-Related Disorders	BACLOFEN, TIAGABINE	Its record names the disease	ClinicalTrials.gov
NCT01030692	Rivastigmine and Huperzine A as Treatments for Cocaine Dependence	Phase 1	72		Cocaine Dependence, Cocaine Addiction, Cocaine Abuse, Substance Abuse	HUPERZINE A, RIVASTIGMINE	Its record names the disease	ClinicalTrials.gov
NCT01601730	Modafinil - Escitalopram Study for Cocaine Dependence	Phase 1	68		Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Substance Abuse	ESCITALOPRAM, MODAFINIL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 29

See all 29 trials

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Computer Delivered CRA + CM + Suboxone vs CM + Suboxone: serious adverse events	0 of 91	0 of 79	170	NCT00929253	Trial comparisons
Citicoline vs Placebo: serious adverse events	1 of 23	2 of 21	44	NCT00223236	Trial comparisons
Aripiprazole vs. Placebo vs Placebo: deaths from any cause	0 of 8	0 of 8	16	NCT00373880	Trial comparisons
Aripiprazole vs. Placebo vs Placebo: serious adverse events	0 of 8	0 of 8	16	NCT00373880	Trial comparisons
Placebo Then n-Acetylcysteine vs n-Acetylcysteine Then Placebo: serious adverse events	0 of 8	0 of 7	15	NCT02141620	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
18571890	RESULT	1	PubMed
18489017	RESULT	1	PubMed
33140994	DERIVED	1	PubMed
26239766	DERIVED	1	PubMed
25090043	DERIVED	1	PubMed
22319592	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004456

GET https://conductscience.org/api/diseases/v1/MONDO_0004456/drugs?page=2

API reference For AI assistants